Anavex Life Sciences (AVXL) Cash from Operations (2010 - 2025)
Anavex Life Sciences (AVXL) reported Cash from Operations of 7151000.0 for Q4 2025, up 41.0% on a YoY basis from 5071690.56 in Q4 2024, and up 16.89% sequentially from 8604000.0 in Q3 2025.
Anavex Life Sciences (AVXL) Cash from Operations (2010 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 16 years of Cash from Operations data on file, last reported at 7151000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 41.0% year-over-year to 7151000.0; the trailing twelve-month figure through Dec 2025 stood at 34075000.0 (up 4.32% YoY), and the FY2025 full-year result was 39044000.0, down 26.72% from the prior year.
- Cash from Operations improved to 7151000.0 in Q4 2025, from 8604000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3500955.0 in Q4 2021 to a low of 12464000.0 in Q2 2025.
- A 5-year average of 7577131.1 and a median of 7317422.5 in 2021 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 55.52% in 2021 and sank 140.62% in 2025, its largest moves.
- Tracing AVXL's Cash from Operations over 5 years: stood at 3500955.0 in 2021, then slumped by 65.5% to 5794000.0 in 2022, then fell by 26.3% to 7318000.0 in 2023, then plunged by 65.62% to 12120000.0 in 2024, then jumped by 41.0% to 7151000.0 in 2025.
- Business Quant data shows AVXL's Cash from Operations at 7151000.0 in Q4 2025, 8604000.0 in Q3 2025, and 12464000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | -7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.15 Mn |
| Dec 31, 2025 | -7.15 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Sep 30, 2023 | -5.85 Mn |
| Sep 30, 2023 | -5.85 Mn |